Rangsima LolekhaSarawut BoonsukTanarak PlipatMichael MartinChaweewan TonputsaNiramon PunsuwanThananda NaiwatanakulKulkanya ChokephaibulkitHansa ThaisriPraphan PhanuphakSuchada ChaivoothSumet OngwandeeBenjamas BaipluthongWachira PengjuntrSopon MektonCDC Thailand/Southeast Asia Regional OfficeThailand Ministry of Public HealthMahidol UniversityThai Red Cross AIDS Research CentreNational Health Security Office2018-12-112019-03-142018-12-112019-03-142016-06-10Morbidity and Mortality Weekly Report. Vol.65, No.22 (2016), 562-5661545861X014921952-s2.0-84973620759https://repository.li.mahidol.ac.th/handle/20.500.14594/40695© 2016, Department of Health and Human Services. All rights reserved. Thailand experienced a generalized human immunodeficiency virus (HIV) epidemic during the 1990s. HIV prevalence among pregnant women was 2.0% and the mother-to-child transmis­sion (MTCT) rate was >20% (1-3). In June 2016, Thailand became the first country in Asia to validate the elimination of MTCT by meeting World Health Organization (WHO) tar­gets. Because Thailand’s experience implementing a successful prevention of MTCT program might be instructive for other countries, Thailand’s prevention of MTCT interventions, outcomes, factors that contributed to success, and challenges that remain were reviewed. Thailand’s national prevention of MTCT program has evolved with prevention science from national implementation of short course zidovudine (AZT) in 2000 to lifelong highly active antiretroviral therapy regardless of CD4 count (WHO option B+) in 2014 (1). By 2015, HIV prevalence among pregnant women had decreased to 0.6% and the MTCT rate to 1.9% (the elimination of MTCT target is <2% for nonbreastfeeding populations) (4). A strong public health infrastructure, committed political leadership, govern­ment funding, engagement of multiple partners, and a robust monitoring system allowed Thailand to achieve this important public health milestone.Mahidol UniversityEnvironmental ScienceHealth ProfessionsArticleSCOPUS10.15585/mmwr.mm6522a2